| Not Yet Recruiting | A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Opt NCT07012044 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia NCT07022678 | Children's Oncology Group | Phase 3 |
| Recruiting | Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leuk NCT06871410 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia NCT07263906 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Recruiting | MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT07025564 | City of Hope Medical Center | Phase 1 |
| Recruiting | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell NCT06928662 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients Wi NCT06484062 | National Cancer Institute (NCI) | Phase 1 |
| Suspended | A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06763341 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Pati NCT06572631 | City of Hope Medical Center | Phase 1 |
| Suspended | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refr NCT06454409 | City of Hope Medical Center | Phase 1 |
| Recruiting | TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes W NCT03816319 | National Cancer Institute (NCI) | Phase 1 |
| Suspended | DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hem NCT06492707 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia NCT06399640 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Recruiting | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and NCT06222580 | Uma Borate | Phase 1 |
| Active Not Recruiting | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leu NCT05146739 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Tazemetostat and Palbociclib With CPX-351for R/R AML NCT05627232 | Thomas Jefferson University | Phase 1 |
| Active Not Recruiting | Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation NCT04203316 | Children's Oncology Group | Phase 2 |
| Withdrawn | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Tr NCT05320380 | Children's Oncology Group | Phase 1 / Phase 2 |
| Terminated | Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acu NCT05799079 | Sanjay Mohan | Phase 2 |
| Recruiting | 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute NCT05263284 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT05441514 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Le NCT05396859 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML a NCT05456269 | Race Oncology Ltd | Phase 1 |
| Active Not Recruiting | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Prev NCT05222984 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who NCT04655391 | City of Hope Medical Center | Phase 1 |
| Recruiting | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure NCT04905810 | Brian Jonas | Phase 2 |
| Terminated | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplast NCT04874194 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute M NCT04975919 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT04956042 | CicloMed LLC | Phase 1 / Phase 2 |
| Recruiting | ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutate NCT05010122 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors NCT05035706 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Withdrawn | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis Af NCT03602898 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relap NCT04774393 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatr NCT04915612 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia NCT04526795 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acu NCT04752163 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia NCT04746235 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic S NCT04493164 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid NCT04250051 | Northwestern University | Phase 1 |
| Recruiting | CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatmen NCT04375631 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced M NCT04146038 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid NCT04207190 | Roswell Park Cancer Institute | Phase 1 |
| Withdrawn | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Fron NCT04493099 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Synd NCT03953898 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia NCT04435691 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or NCT04487106 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML NCT04220684 | Sumithira Vasu | Phase 1 |
| Recruiting | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia an NCT04128748 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leuk NCT04188405 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT04196010 | University of Washington | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytar NCT03983824 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or My NCT03969446 | City of Hope Medical Center | Phase 1 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid NCT03701295 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia NCT04158739 | Children's Oncology Group | Phase 1 |
| Withdrawn | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem C NCT03807063 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute My NCT04140487 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation NCT03881735 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Re NCT04047641 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Le NCT04013880 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or NCT03874052 | Jennifer Saultz | Phase 1 |
| Recruiting | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Ris NCT03670966 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelody NCT03772925 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute NCT03745352 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refract NCT03813147 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | CPX-351 Plus Enasidenib for Relapsed AML NCT03825796 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Withdrawn | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia NCT03752138 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies NCT02530034 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukem NCT03735875 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurren NCT03634228 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or NCT03672539 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leuk NCT03661307 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractor NCT03629171 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Re NCT03600155 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia NCT03557970 | OHSU Knight Cancer Institute | Phase 2 |
| Active Not Recruiting | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Diso NCT03289910 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 G NCT03683433 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malig NCT03471260 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients W NCT03041688 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute NCT03390296 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplast NCT03067571 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory A NCT03214562 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute M NCT02890329 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia NCT03009240 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia U NCT03247088 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leuk NCT03132454 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is NCT03063944 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Terminated | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia NCT02953561 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid NCT02882321 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grad NCT02756572 | University of Washington | Phase 2 |
| Active Not Recruiting | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer U NCT02861417 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplasti NCT02684162 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Personalized NK Cell Therapy in CBT NCT02727803 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leu NCT02649764 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome NCT02392572 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory NCT02551718 | University of Washington | N/A |
| Completed | 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02509546 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Terminated | Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia NCT02399917 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Di NCT02397720 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferati NCT02257138 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk NCT02115295 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leuke NCT01904136 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in R NCT02083250 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leuk NCT01892371 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Tran NCT01822509 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplasti NCT01640301 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelog NCT01620216 | OHSU Knight Cancer Institute | Phase 2 |